Home › Research › Topics › metabolic-syndrome
metabolic-syndrome
304 studies tagged metabolic-syndrome, dated 1984-04-01 to 2026-10-26. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Interventions for Cognitive Impairment in Type 2 Diabetes Mellitus: An Umbrella Review of Pharmacological and Lifestyle Strategies, Mechanisms, and Clinical Implications 2026-10-26
- Visit-to-Visit Blood Pressure Variability, Glycemic Status and the Risk of Dementia, Stroke, and All-Cause Mortality: A UK Biobank Cohort Study 2026-10-13
- Plasma metabolomic profiling of frailty in older adults at risk of dementia 2026-10-08
Studies
304 studies carry this tag.
Date range
1984 to 2026
Top journals
- Journal of Alzheimer's disease : JAD 21
- medRxiv 16
- Alzheimer's & dementia : the journal of the Alzheimer's Association 14
- Neurology 10
- Nutrients 10
164 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Emerging evidence of brain injury on risk of neurodegenerative diseases such as Alzheimer's disease (AD) and chronic traumatic encephalopathy (CTE) have resulted in interest in therapeutic potential of omega-3 fatty acids (n-3FA).
-
Evidence from epidemiological studies on the general population suggests that midlife cardiovascular disease (CVD) and/or metabolic syndrome (MetS) are associated with an increased risk of cognitive impairment and dementia later in life.
-
Risk of early-onset dementia (EOD) might be modified by environmental factors and lifestyles, including diet.
-
59/100
To investigate the correlation between hypertension development and the progression of mild cognitive impairment (MCI) to dementia in middle-aged and elderly people.
-
Benefits and risks of statins relative to neurological outcomes should be considered when prescribed for at-risk NDD populations.
-
The relationship between arterial hypertension and cognitive decline, two among the conditions with higher prevalence in the elderly population, has gained significant interest, in the scientific community, during the last few years, stemming from the numerous epidemiologic, experimental, and therapeutic evidences suggesting a non-casual correlation between the two conditions.
-
A difference between subjects with and without obesity and memory scores was shown by t tests.
-
The prospective cohort data from the JPSC-AD will provide valuable insights regarding the risk factors and etiology of dementia as well as for the development of predictive models and diagnostic markers for the future onset of dementia.
-
A variety of potentially modifiable risk factors have been investigated in an attempt to delay/prevent Alzheimer's disease (AD).
-
We included 201 individuals (mean age 73.5 years, mean BMI 27.4 kg/m2).
-
Evidence-based suggestions are proposed, offering clinicians and stakeholders current guidance for the prevention of AD.
-
The prevention or alleviation of neurodegenerative diseases, including Alzheimer's disease (AD), is a challenge for contemporary health services.
-
Innumerable studies have suggested "the lower, the better" for cardiovascular risk factors, such as body weight, lipid profile, blood pressure, and blood glucose, in terms of health outcomes.
-
RECENT FINDINGS: Specific dietary patterns and varied nutrient combinations can have a protective effect on brain health, promote cognitive function, and mediate the comorbidity of chronic conditions associated with increased AD risk.
-
This analysis indicated that patients with type 2 diabetes under treatment with DPP-4 inhibitors presented with the lowest risk of dementia, followed by those treated with metformin and thiazolidinedione, while treatment with insulin was associated with the highest risk.
-
Arterial hypertension is considered the main modifiable vascular risk factor that causes silent damage to brain vessels.
-
Dementias, and Alzheimer's disease (AD) in particular, will increasingly become a public health issue.
-
Atrial fibrillation (AF) is associated with increased risk of cognitive impairment and dementia, even with no overt stroke.
-
Among patients with breast cancer, tamoxifen and steroidal aromatase inhibitors were associated with a decrease in the number who received a diagnosis of NDD, specifically Alzheimer disease and dementia.
-
In the past decade a large body of evidence has accumulated on risk factors for dementia, primarily from Europe and North America.
-
Alzheimer's Disease (AD) incidence is increasing and with no disease modifying agents available, preventative measures through lifestyle factors are being investigated.
-
The median time interval between FSRP and death was 33.4 years for mid-life FSRP and 4.4 years for final FSRP measurement before death.
-
Use of metformin, DPP4 inhibitors, GLP1 analogs and SGLT2 inhibitors was associated with lower risk of dementia in patients with diabetes.
-
Adjusted differences showed advantages in the 6-year change in STICS-m score of 0.25 (95% CI 0.04-0.45) for an increase of 1-SD (9 points) in the AHEI-2010 and of 0.27 (95% CI 0.05-0.48) for an increase of 1-SD (1.5 points) in the MIND diet.
-
The prevalence of dementia worldwide is growing at an alarming rate.
-
Cerebrovascular risk factors are associated with Parkinson disease, an effect comparable to their association with Alzheimer disease.
-
In a large international cardiovascular outcome trial in people with type 2 diabetes and cardiorenal disease, linagliptin did not modulate cognitive decline over 2.5 years.
-
APOE-ε4 carrier status appears to modify the cross-sectional association between cardiac output and neuropsychological performance such that lower cardiac output relates to poorer performances among carriers of the ε4 allele.
-
The score improvement in the global Clinical Dementia Rating (gloCDR) was superior in the active group than placebo (p = 0.023).
-
55/100
Totally 30,332 patients (5.6%) were diagnosed with dementia during the follow-up, with 14,097 men (4.9%) and 16,235 women (6.5%).
-
Due to the small number of studies and heterogeneity in study design and outcomes, the association between DNA methylation age and age-related disease and longevity is inconclusive.
-
54/100
Lower HDL-C was significantly associated with a higher odds of cognitive impairment (OR 2.70 per 1 mmol/L reduction; 95% CI 1.25, 5.56; p = 0.011), whereas BMI, TG, glucose and HbA1c were not (all p > 0.05).
-
55/100
Atrial fibrillation (AF) is one of the cardiovascular risk factors for dementia.
-
63/100
To examine the association between blood cholesterol concentrations and Alzheimer's disease (AD) in the Chinese elderly.
-
An increasing aging population worldwide accounts for a growing share of noncommunicable diseases (NCDs) of the overall social and economic burden.
-
There is a lack of midlife specific data, limited data on VaD, and a lack of geographical representation for many risk factors for dementia.
-
71/100
A total of 32,901 (1.12%) participants developed dementia, of which 74.4% and 11.0% were attributable to Alzheimer's disease and vascular dementia, respectively, during the median follow-up of 5.5 years.
-
39/100
Present demographic changes demonstrate that the number of elderly people is growing at a frenetic pace.
-
Strong evidence has emerged recently for the concept that herpes simplex virus type 1 (HSV1) is a major risk for Alzheimer's disease (AD).
-
There are a paucity of data regarding the role of gender and atrial fibrillation (AF) on cognitive decline and incidence of dementia.
-
72/100
In this cohort of older adults, increased numbers of optimal cardiovascular health metrics and a higher cardiovascular health score were associated with a lower risk of dementia and lower rates of cognitive decline.
-
As outlined in the original cohort profile,1 The Irish Longitudinal Study on Ageing (TILDA) is a prospective cohort study designed to provide an evidence base for addressing the challenges and opportunities associated with population ageing in Ireland.
-
This study (registered with PROSPERO, CRD42018085967) compares the efficacy (i.e. pro-cognitive effects) and acceptability of antidiabetic agents for Alzheimer's disease (AD) and mild cognitive impairment (MCI).
-
59/100
Metabolically healthy obese (MHO) individual is known to be defended from the metabolic complications of obesity.
-
We reviewed the most recent literature examining the associations between the Mediterranean-style diet (MD), neurodegenerative diseases, and markers and mechanisms of neurodegeneration.
-
Nearly 30% of adults 40 years and older in the United States are on a statin.
-
A total of 165 cognitively normal participants of the Baltimore Longitudinal Study of Aging (BLSA) Neuroimaging substudy, aged 55-92 years (mean baseline age = 76.4 years, 85 participants were male), received an average of 2.5 PET-PiB scans over an average interval of 2.6 (3.08 SD) years between first and last visits.
-
In this review, we will discuss the possible mechanisms which may relate the association between MetS and cognitive decline which include vascular damages, elevation of reactive oxygen species (ROS), insulin resistance and low-grade inflammation.
-
These results provide support that higher educational attainment is associated with a reduced risk of Alzheimer's disease.
-
Daily oral DHA supplementation (2 g/day) for 24 months may improve cognitive function and change blood biomarker-related Aβ-mediated autophagy in people with MCI.
From across this tag
6 of the 304 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 6. The same 6 appear here every time.
- Dietary Fats and the Risk of Incident Alzheimer Disease
- Increased risk of type 2 diabetes in Alzheimer disease
- Correlations between Cognitive Evaluation and Metabolic Syndrome
- Cardiovascular Risk Management in Persons with Dementia
- MIND Diet Impact on Multiple Sclerosis Patients: Biochemical Changes after Nutritional Intervention
- Dietary factors and Alzheimer's disease risk: a Mendelian randomization study